Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews skin disorders in Parkinson's disease, highlighting the potential of skin studies and stem cell research to advance understanding and treatment of the neurodegenerative disorder, without presenting new results.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.

This review evaluated the evidence on skin disorders linked to levodopa treatment for Parkinson's disease, suggesting a possible association with melanoma, though evidence remains inconclusive and further studies are needed.

This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.

The interdisciplinary approach improved the quality of life for a Parkinson's patient and eased staff workload.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

This article reviews drug-induced hair changes, highlighting that while many drugs are occasionally linked to hair loss, this connection has been conclusively established for only a few, and such hair loss is typically reversible.

This review discusses medication-induced gray hair repigmentation, highlighting that certain anti-inflammatory drugs and melanogenesis stimulators can cause diffuse repigmentation, though evidence remains low-quality and these medications are not currently indicated for this purpose.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This review discusses the link between Parkinson's disease and dermatological disorders, highlighting that skin biomarkers may aid in the diagnosis of Parkinson's, but it reports no new clinical results.

The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.

This article contains additional supporting information available online but presents no new research findings.

Finasteride may help reduce symptoms in male Tourette syndrome patients.

The document describes a woman with familial Parkinson's disease due to a genetic mutation, showing severe symptoms and poor response to treatment, and suggests finasteride may help reduce symptoms in Tourette syndrome.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.

THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.

This study found that while GPT-4 shows high accuracy and efficiency in clinical decision making, physicians' critical thinking and lifelong learning skills remain essential, particularly in addressing and interpreting AI errors in medical settings.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.

Finasteride may help reduce tic severity in male Tourette syndrome patients.

A woman's unique dementia was misdiagnosed, a genetic mutation increases Parkinson's risk with age, and finasteride may help with Tourette syndrome.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This study found that the natural polymer-based hydrogel Gel/SA@PL released growth factors in a controlled way, which enhanced tissue regeneration and minimized scarring in the healing of diabetic wounds.

This report details a six-month pharmacy internship in Portugal, where the author engaged in hospital and community pharmacy settings, and discusses scientific topics including obesity medication risks and alopecia treatment options. Results and conclusions are not explicitly reported.

This study focused on developing a nanoemulsion-based gel for delivering minoxidil, aiming to enhance its contact time with the scalp and potentially improve skin absorption compared to conventional topical solutions.

This study found that in thin cutaneous melanomas, tumor regression is associated with a higher risk of sentinel lymph node involvement.

This article reviews how various drugs may cause hair loss, stimulate growth, or alter hair characteristics, but reports no new clinical results; drug-induced hair loss is typically reversible.

This report describes two cases of sustained hair repigmentation related to porphyria cutanea tarda, though the underlying mechanism remains unclear.

This study reviewed the dosages of products approved in Japan from 2003-2010 and found that 28.1% were at different levels than in the U.S., with limited evidence suggesting different clinical responses.